Early trial of M1069 for advanced cancers halted
NCT ID NCT05198349
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This early-stage study tested a new drug called M1069 in 15 people with advanced solid tumors that had spread or couldn't be removed. The main goal was to check safety and find the right dose. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC OR LOCALLY ADVANCED UNRESECTABLE SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Princess Margaret Cancer Centre
Toronto, Canada
-
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.